|
|
|
|
|
Lomustine
drug data and news
Lomustine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Lomustine | ||
| Brand Names/Synonyms | Belustine; CCNU; CCRIS 860; CHEMBANK4359; Ccnu [Chloroethyl Nitrosoureas]; Cecenu; Ceenu; Ceenu®; Chloroethylcyclohexylnitrosourea; Cinu; Cyclohexyl Chloroethyl Nitrosourea; HSDB 6519; ICIG 1109; Lomustina [Inn-Spanish]; Lomustine; Lomustine [Usan:Ban:Inn]; Lomustinum [Inn-Latin]; RB 1509; SRI 2200; [Inn-Spanish] | ||
| Indication | For use as a single agent in addition to other treatment modalities to treat brain tumors and Hodgkin's disease | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Although it is generally agreed that CeeNU alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. | ||
| Mechanism Of Action | Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents | ||
| Lomustine News (When available) |
Zanosar® Superior to Doxorubicin for Advanced Carcinoid Tumors Aug 2, 2005 New Regimen Effective for Relapsed Non-Hodgkin’s Lymphoma Jul 18, 2005 Clinical Data Presented at SNM Annual Meeting Demonstrates Both ... Jun 21, 2005 Clinical Data Presented at SNM Annual Meeting Demonstrates Both ... Jun 21, 2005 New Regimen Effective For Refractory non-Hodgkin's Lymphoma Jun 3, 2005 | ||
| Dosage Forms | CAPSULES | ||
| Drug_Category | Antineoplastic Agents; ATC:L01AD02 | ||
| Absorption | Rapidly and completely absorbed (in 30-60 minutes) | ||
| Interactions |
Interactions for Lomustine: No Information Provided. | ||
| Toxicity | Myelosuppression is cumulative; after repeated courses of treatment, recovery of blood cell count is slower and bone marrow hypoplasia may persist, Pulmonary toxicity has been reported at cumulative doses usually greater than 1,100 mg/m2. There is one report of pulmonary toxicity at a cumulative dose of only 600 mg. The onset of toxicity has varied from 6 months after initiation of therapy, to as late as 15 years after. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea | ||
| Chemical Formula | C9H16ClN3O2 | ||
| Molecular Weight | 233.695 g/mol | ||
| Smiles String | C1CCC(CC1)NC(=O)N(CCCl)N=O | ||
| Melting Point | 90 °C | ||
| Water Solubility | 111 mg/L | ||
| State | Solid, yellow powder | ||
| LogP/Hphobicity | 2.629 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic, rapid and complete, with active metabolites | ||
| Half Life | 16 hours-2 days | ||
| Protein Binding [%] | 50% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Lomustine.html http://www.rxlist.com/cgi/generic2/lomustine.htm http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00292 | ||
| CAS Registry Number | 13010-47-4 | ||
| KEGG Compound ID | D00363 | ||
| PubChem ID | SID:168381 | ||
| PharmGKB ID | PA450261 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 360430 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |